check_circleStudy Completed
Ovarian neoplasms
Bayer Identifier:
91476
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
ZK-Epo given with carboplatin in patients with recurrent ovarian cancer
Trial purpose
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.
Key Participants Requirements
Sex
FemaleAge
18 YearsTrial summary
Enrollment Goal
45Trial Dates
August 2006 - March 2009Phase
Phase 2Could I Receive a placebo
NoProducts
Sagopilone (BAY86-5302)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Albuquerque, 87131, United States | |
Completed | Little Rock, 72205, United States | |
Completed | Toronto, M4N 3M5, Canada | |
Completed | Savannah, 31404, United States | |
Completed | Roanoke, 24014, United States | |
Completed | Bakersfield, 93309, United States | |
Completed | Cleveland, 44109, United States | |
Completed | Calgary, T2N 4N2, Canada | |
Completed | Winston-Salem, 27157, United States | |
Completed | Baltimore, 21204, United States | |
Completed | Oklahoma City, 73104, United States | |
Completed | Knoxville, 37920, United States | |
Completed | South Bend, 46617, United States | |
Completed | San Diego, 92121, United States | |
Completed | Tucson, 85724, United States | |
Completed | La Jolla, 92093, United States |
Primary Outcome
- Response to treatment with ZK-Epo after 6 cyclesdate_rangeTime Frame:After 6 cyclesenhanced_encryptionnoSafety Issue:
Secondary Outcome
- Safety and tolerability of ZK-Epo given with carboplatindate_rangeTime Frame:Sept. 2008enhanced_encryptionyesSafety Issue:
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
Non-randomizedBlinding
Open LabelAssignment
Single Group AssignmentTrial Arms
1